Privia Health Group, Inc. Revenue from Contract with Customer, Including Assessed Tax
Privia Health Group, Inc. (PRVA) reported Revenue from Contract with Customer, Including Assessed Tax of $632.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-08-06
- Privia Health Group, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-06-30 was $632.63M, a 21.39% increase year-over-year.
- Privia Health Group, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $603.85M, a 25.78% increase year-over-year.
- Privia Health Group, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $541.17M, a 17.42% increase year-over-year.
- Privia Health Group, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $580.42M, a 32.54% increase year-over-year.
- Privia Health Group, Inc. revenue from contract with customer, including assessed tax for fiscal 2025 was $2.12B, a 22.26% increase from fiscal 2024.
- Privia Health Group, Inc. revenue from contract with customer, including assessed tax for fiscal 2024 was $1.74B, a 4.74% increase from fiscal 2023.
- Privia Health Group, Inc. revenue from contract with customer, including assessed tax for fiscal 2023 was $1.66B, a 22.19% increase from fiscal 2022.
- Privia Health Group, Inc. revenue from contract with customer, including assessed tax for fiscal 2022 was $1.36B, a 40.41% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $632.63M 10-Q · filed 2026-08-06 | $1.24B 10-Q · filed 2026-08-06 | $1.78B derived: sum of 3 quarters · filed 2026-08-06 | $2.36B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $603.85M 10-Q · filed 2026-05-07 | $1.15B derived: sum of 2 quarters · filed 2026-05-07 | $1.73B derived: sum of 3 quarters · filed 2026-05-07 | $2.25B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $541.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.12B derived: sum of 2 quarters · filed 2026-02-27 | $1.64B derived: sum of 3 quarters · filed 2026-08-06 | $2.12B 10-K · filed 2026-02-27 |
| 2025-09-30 | $580.42M 10-Q · filed 2025-11-06 | $1.10B derived: sum of 2 quarters · filed 2026-08-06 | $1.58B 10-Q · filed 2025-11-06 | $2.04B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $521.15M 10-Q · filed 2026-08-06 | $1.00B 10-Q · filed 2026-08-06 | $1.46B derived: sum of 3 quarters · filed 2026-08-06 | $1.90B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $480.10M 10-Q · filed 2026-05-07 | $941.00M derived: sum of 2 quarters · filed 2026-05-07 | $1.38B derived: sum of 3 quarters · filed 2026-05-07 | $1.80B derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $460.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $898.82M derived: sum of 2 quarters · filed 2026-02-27 | $1.32B derived: sum of 3 quarters · filed 2026-02-27 | $1.74B 10-K · filed 2026-02-27 |
| 2024-09-30 | $437.92M 10-Q · filed 2025-11-06 | $860.25M derived: sum of 2 quarters · filed 2025-11-06 | $1.28B 10-Q · filed 2025-11-06 | $1.72B derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $422.33M 10-Q · filed 2025-08-07 | $837.57M 10-Q · filed 2025-08-07 | $1.28B derived: sum of 3 quarters · filed 2026-02-27 | $1.70B derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $415.24M 10-Q · filed 2025-05-08 | $856.07M derived: sum of 2 quarters · filed 2026-02-27 | $1.27B derived: sum of 3 quarters · filed 2026-02-27 | $1.69B derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $440.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $858.11M derived: sum of 2 quarters · filed 2026-02-27 | $1.27B derived: sum of 3 quarters · filed 2026-02-27 | $1.66B 10-K · filed 2026-02-27 |
| 2023-09-30 | $417.28M 10-Q · filed 2024-11-07 | $830.63M derived: sum of 2 quarters · filed 2024-11-07 | $1.22B 10-Q · filed 2024-11-07 | $1.58B derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $413.35M 10-Q · filed 2024-08-08 | $799.63M 10-Q · filed 2024-08-08 | $1.16B derived: sum of 3 quarters · filed 2025-02-27 | $1.51B derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $386.28M 10-Q · filed 2024-05-09 | $750.70M derived: sum of 2 quarters · filed 2025-02-27 | $1.09B derived: sum of 3 quarters · filed 2025-02-27 | $1.43B derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $364.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $707.32M derived: sum of 2 quarters · filed 2025-02-27 | $1.04B derived: sum of 3 quarters · filed 2025-02-27 | $1.36B 10-K · filed 2025-02-27 |
| 2022-09-30 | $342.90M 10-Q · filed 2023-11-03 | $678.43M derived: sum of 2 quarters · filed 2023-11-03 | $992.24M 10-Q · filed 2023-11-03 | $1.27B derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $335.54M 10-Q · filed 2023-08-03 | $649.34M 10-Q · filed 2023-08-03 | $924.67M derived: sum of 3 quarters · filed 2024-02-27 | $1.18B derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $313.80M 10-Q · filed 2023-05-04 | $589.13M derived: sum of 2 quarters · filed 2024-02-27 | $840.66M derived: sum of 3 quarters · filed 2024-02-27 | $1.07B derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $275.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $526.86M derived: sum of 2 quarters · filed 2024-02-27 | $752.61M derived: sum of 3 quarters · filed 2024-02-27 | $966.22M 10-K · filed 2024-02-27 |
| 2021-09-30 | $251.52M 10-Q · filed 2022-11-10 | $477.28M derived: sum of 2 quarters · filed 2022-11-10 | $690.89M 10-Q · filed 2022-11-10 | $904.59M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $225.76M 10-Q · filed 2022-08-11 | $439.36M 10-Q · filed 2022-08-11 | $653.06M derived: sum of 3 quarters · filed 2023-03-01 | $860.23M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $213.61M 10-Q · filed 2022-05-12 | $427.31M derived: sum of 2 quarters · filed 2023-03-01 | $634.48M derived: sum of 3 quarters · filed 2023-03-01 | $817.74M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $213.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $420.87M derived: sum of 2 quarters · filed 2023-03-01 | $604.13M derived: sum of 3 quarters · filed 2023-03-01 | $817.08M 10-K · filed 2023-03-01 |
| 2020-09-30 | $207.17M 10-Q · filed 2021-11-08 | $390.43M derived: sum of 2 quarters · filed 2021-11-08 | $603.38M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $183.26M 10-Q · filed 2021-08-09 | $396.21M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $212.94M 10-Q · filed 2021-05-28 | |||
| 2019-12-31 | $786.36M 10-K · filed 2022-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |